Pharmacogenomics (PGx) is the study of inherited, unique-to-patient DGI risk. Many commonly prescribed drugs have known risk of DGI. PGx testing finds these risk helping to: lower risk of drug toxicity, harmful side effects, HRU, and improve therapy outcomes.
Consulting & Facilitation of Pharmacogenomic Testing in Clinical Practice
PGx: The Future of Pharmacy. Adverse Drug Events (ADEs) are the 4th leading cause of death in the USA every year. These unintended and harmful responses can occur at commonly prescribed doses. Pharmacogenomic (PGx) testing allows prescribers to make more informed medication choices by assessing individual patient genetic information as it directly relates to their ability to process a range of chemical substances that use the CYP450 Enzyme System; including prescription, over-the-counter, herbals, and recreational drugs. Our partnership with Genelex Labs allows us to bring PGx testing to clinical practice at an affordable price. Support of their innovative software platform, YouScript, allows medication recommendations to be easily accessed and understood.
What do genes have to do with drugs?
Research & understanding of the human genome in recent years has given insight into new, more effective treatments for a variety of diseases. The cornerstone of NGM RxHealth is pharmacogenomic testing, or ‘PGx’. Pharmacogenomic testing is a non-invasive, highly informative medical tool that identifies genetic variations in the human genome that directly correlate to the patient’s ability to metabolize drugs. These variations are the reason that the same drug at the standard acceptable dose works well for one patient, has little effect in another, and in the worst cases, has a toxic result.
Adverse Drug Events (ADEs) create serious burden to patient quality of life and the healthcare system. Each year, ADEs add $289 billion to healthcare costs, and are the 4th leading cause of death. Annual data from the U.S. Center for Disease Control and Prevention, and the Journal of the American Medical Association cite 2.2 million adverse drug reactions; and 100,000 deaths occurring from properly prescribed drugs. Current medication prescribing practices rely on trial-and-error periods to determine medication efficacy. This period is the point at which ADEs often occur.
At NGM RxHealth, we believe that incorporating PGx testing into routine clinical practice is key to avoiding ADEs, decreasing healthcare costs, and most importantly, improving patient quality of life. In numerous studies and publications, PGx testing has shown these promising results. It is necessary to continue to gather research and data before PGx can become truly standard, and we are dedicated to assisting and facilitating that process. Whether you’re a physician or patient, contact us today to learn more about the promise of PGx, our services, and how to get tested.
Learn more about our partner PGx testing lab, Genelex, at: www.genelex.com